Intriguing BCMA-Targeted Therapies Move Through Myeloma Pipeline

Ellie Leick
Published: Wednesday, Nov 27, 2019
David E. Avigan, MD, a professor of medicine at Harvard Medical School and active staff in Hematology-Oncology at Beth Israel Deaconess Medical Center

David E. Avigan, MD

Investigators are exploring various treatment modalities in the multiple myeloma pipeline, many of them using BCMA as a target because of its high expression on myeloma cells, explained David E. Avigan, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication